The SENSible Blog discusses the development of rejuvenation biotechnology around the world: progress being made in the field of longevity, the design of medical therapies to cure, reverse and prevent the diseases and disabilities of aging, and much more.

Our content is a blend of popular interest articles – labelled “Easy Reads”, and designed to require no specific background knowledge – as well as more detailed scientific commentaries, labelled as “In-Depth” and aimed towards readers with some grounding in the biological/medical sciences.

In-Depth

How to Disable a Cellular Bomb: Findings and Tools on the Machinery of ALT

APBs – protein complexes associated with telomeric DNA in ALT (Alternative Lengthening of Telomeres) cancer cells – are the leading candidates for the sub-cellular site at which the ALT mechanism occurs. Recent work involving the generation of artificial APBs has shed light on their composition and function, providing hints as to how ALT might be disabled.

Read More »
In-Depth

With True Cells Come True Benefits: the Potential of Human Pluripotent Stem Cells Released in a Model of Parkinson’s Disease

Parkinson’s disease is characterised by the loss of dopaminergic neurons from the substantia nigra, and cell therapy is being actively pursued as a means to replace the losses. Most trials to date have used fetal tissue, an approach that although transiently effective is unscalable and prone to immune rejection. Human dopaminergic neurons differentiated from stem cells have historically had poor therapeutic efficiency, but a new study using an improved differentiation protocol has shown much more positive results.

Read More »
In-Depth

Novel Abeta Vaccine Reports First Human Data

Aggregates of beta-amyloid protein (Abeta) and other malformed proteins accumulate in both “normal” brain aging and neurodegenerative disease, leading to neuronal loss. Their removal by immunotherapy is a central plank of the SENS platform, and the most clinically advanced. Gantenerumab, a new fully human anti-Abeta monoclonal antibody, has just completed a Phase I trial.

Read More »
In-Depth

A Green Light for the Ultimate Cure for Cancer

The elimination from the body of telomerase, the enzyme used by most cancer cells to maintain their DNA through unlimited numbers of cell divisions, is the central component of the WILT (Whole-body Interdiction of Lengthening of Telomeres) strategy proposed by SENS Research Foundation as a universal and unbreachable defence against all forms of cancer. Concerns have been raised, however, that telomerase may have other biologically important functions, making its elimination dangerous or impossible. Fortunately, recent work by Nobel laureate Carol Greider indicates a lack of any such activity.

Read More »
Easy Read

From AGE to SENS5: Building Momentum For Human Rejuvenation

The fifth biannual Strategies for Engineered Negligible Senescence biomedical conference is just days away. Getting ready for the trip has cast my mind back not only to previous meetings of this exciting interdisciplinary series, and also to the recent 40th meeting of the American Aging Association (AGE). AGE was the first, and remains the premier, professional scientific organization focused specifically on biomedical research in aging.

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2022 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can